Found: 8
Select item for more details and to access through your institution.
Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. 1, doi. 10.3389/fimmu.2020.00745
- By:
- Publication type:
- Article
Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study.
- Published in:
- Toxicologic Pathology, 2022, v. 50, n. 5, p. 712, doi. 10.1177/01926233221100168
- By:
- Publication type:
- Article
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab.
- Published in:
- Science Translational Medicine, 2023, v. 15, n. 681, p. 1, doi. 10.1126/scitranslmed.abq5068
- By:
- Publication type:
- Article
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.
- Published in:
- Science Translational Medicine, 2023, v. 15, n. 681, p. 1, doi. 10.1126/scitranslmed.abq5241
- By:
- Publication type:
- Article
Minipigs in Translational Immunosafety Sciences.
- Published in:
- Toxicologic Pathology, 2016, v. 44, n. 3, p. 315, doi. 10.1177/0192623315621628
- By:
- Publication type:
- Article
Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
- Published in:
- PLoS Pathogens, 2020, v. 16, n. 4, p. 1, doi. 10.1371/journal.ppat.1008477
- By:
- Publication type:
- Article
Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus Monkeys.
- Published in:
- Toxicological Sciences, 2018, v. 166, n. 1, p. 192, doi. 10.1093/toxsci/kfy196
- By:
- Publication type:
- Article